Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial.

Saved in:
Bibliographic Details
Title: Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial.
Authors: Martin-Broto J; Medical Oncology Department, University Hospital Fundación Jimenez Diaz, Madrid, Spain. jmartin@mustbesevilla.org.; University Hospital General de Villalba, Madrid, Spain.; Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS/FJD), Madrid, Spain., Lopez-Alvarez M; Institute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain., Moura DS; Institute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain., Ramos R; Pathology Department, University Hospital Son Espases, Mallorca, Spain., Collini P; Soft Tissue and Bone Pathology, Histopathology and Pediatric Pathology Unit, Diagnostic Pathology and Laboratory Medicine Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Nazionale Tumori, Milan, Italy., Romagosa C; Pathology Department, University Hospital Vall D'Hebron, Barcelona, Spain.; Centro de Investigación Biomédica en RED (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain., Bagué S; Pathology Department, Santa Creu I Sant Pau Hospital, Barcelona, Spain., Renne SL; Anatomic Pathology Unit, Humanitas Clinical and Research Center - IRCCS -, Rozzano (MI), Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy., Barisella M; Soft Tissue and Bone Pathology, Histopathology and Pediatric Pathology Unit, Diagnostic Pathology and Laboratory Medicine Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Nazionale Tumori, Milan, Italy., Velasco V; Pathology Department, Service d'Anatomie Pathologique, Institut Bergonié, Bordeaux, France., Coindre JM; Bergonie Institute, Department of Biopathology, Bordeaux, and Bordeaux University, Talence, France., Lopez-Lopez D; Institute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain.; Clinical Bioinformatics Area. Fundación Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, Sevilla, Spain.; Bioinformatics in Rare Diseases (BiER). Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), FPS, Hospital Virgen del Rocio, Sevilla, Spain., Dopazo J; Institute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain.; Clinical Bioinformatics Area. Fundación Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, Sevilla, Spain.; Bioinformatics in Rare Diseases (BiER). Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), FPS, Hospital Virgen del Rocio, Sevilla, Spain.; INB-ELIXIR-es FPS, Hospital Virgen del Rocío, Sevilla, Spain., Gambarotti M; Department of Anatomy and Pathological Histology, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy., Braglia L; Research and Statistics Infrastructure, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy., Merlo DF; Research and Statistics Infrastructure, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy., Palmerini E; Chemotherapy Unit, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy., Stacchiotti S; Cancer Medicine Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale Tumori, Milan, Italy., Quagliuolo VL; Department of Surgery, Istituto Clinico Humanitas, Rozzano, Italy., Lopez-Pousa A; Medical Oncology Department, Santa Creu I Sant Pau Hospital, Barcelona, Spain., Grignani G; Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy., Blay JY; Department of Medical Oncology, Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon, France., Brunello A; Department of Oncology, Medical Oncology 1 Unit, Istituto Oncologico Veneto IOV, IRCCS, Padova, Italy., Gutierrez A; Hematology Department, Son Espases University Hospital, Mallorca, Spain., Valverde C; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Hindi N; Medical Oncology Department, University Hospital Fundación Jimenez Diaz, Madrid, Spain.; University Hospital General de Villalba, Madrid, Spain.; Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS/FJD), Madrid, Spain., Dei Tos AP; Department of Pathology, Treviso General Hospital, Treviso, Italy.; University of Padua, Padova, Italy., Picci P; Laboratory of Oncologic Research, Istituto Ortopedico Rizzoli, Bologna, Italy., Casali PG; Cancer Medicine Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale Tumori, Milan, Italy., Gronchi A; Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2021 Dec; Vol. 20 (12), pp. 2539-2552. Date of Electronic Publication: 2021 Sep 22.
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1538-8514
DOI:10.1158/1535-7163.MCT-21-0315